{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:15:33Z","timestamp":1784862933511,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.07.001","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T12:53:48Z","timestamp":1688993628000},"page":"815-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Bowser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-5937","authenticated-orcid":false,"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2023.07.001_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2023.07.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000242","article-title":"Front-line treatment of multiple myeloma","volume":"3","author":"Cavo","year":"2019","journal-title":"HemaSphere"},{"issue":"3","key":"10.1016\/j.clml.2023.07.001_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.07.001_sbref0004","volume":"3","year":"2023"},{"issue":"1","key":"10.1016\/j.clml.2023.07.001_bib0005","doi-asserted-by":"crossref","first-page":"21916","DOI":"10.1038\/s41598-021-01440-x","article-title":"Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Kiss","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clml.2023.07.001_bib0006","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/hematology.2020000109","article-title":"Sequencing multiple myeloma therapies with and after antibody therapies","volume":"2020","author":"van de Donk","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2023.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0008","article-title":"First-line use of daratumumab, lenalidomide, and dexamethasone confers survival benefit compared with second-line use of daratumumab-based regimens in transplant-ineligible patients with multiple myeloma: analysis of different clinical scenarios","volume":"138","author":"Fonseca","year":"2021","journal-title":"Blood"},{"issue":"10068","key":"10.1016\/j.clml.2023.07.001_bib0009","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2023.07.001_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2023.07.001_bib0011","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.clml.2023.07.001_bib0012","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"10218","key":"10.1016\/j.clml.2023.07.001_bib0013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0014","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1182\/blood-2022-163335","article-title":"Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.001_bib0015","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1016\/S2152-2650(21)01950-9","article-title":"MM-155: phase 3 MAIA study: overall survival (OS) results with daratumumab, lenalidomide, and dexamethasone (D-Rd) <em>vs<\/em>lenalidomide and dexamethasone (Rd) in Patients with transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM)","volume":"21","author":"Orlowski","year":"2021","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2023.07.001_bib0016","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bjh.18295","article-title":"Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review","volume":"199","author":"McCaughan","year":"2022","journal-title":"Br J Haematol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.07.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8035","article-title":"Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA","volume":"37","author":"Usmani","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.07.001_bib0018","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.07.001_bib0019","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0020","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2022-159933","article-title":"A Dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial","volume":"140","author":"Manier","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.07.001_bib0021","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1093\/oncolo\/oyac067","article-title":"Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma","volume":"27","author":"Jakubowiak","year":"2022","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.clml.2023.07.001_bib0022","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2023.07.001_sbref0023","series-title":"For Newly Diagnosed Myeloma, Are Four Drugs Better Than Three?","author":"Lipe","year":"2021"},{"issue":"14","key":"10.1016\/j.clml.2023.07.001_bib0024","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2023.07.001_bib0025","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood.2020008735","article-title":"How I treat frontline transplantation-eligible multiple myeloma","volume":"139","author":"Perrot","year":"2022","journal-title":"Blood"},{"issue":"10192","key":"10.1016\/j.clml.2023.07.001_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clml.2023.07.001_bib0027","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2020-0266","article-title":"Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison","volume":"13","author":"Moreau","year":"2021","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.clml.2023.07.001_bib0028","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.001_bib0029","series-title":"Presented at the 19th International Myeloma Society Annual Meeting","article-title":"Daratumumab (dara)\u00a0+\u00a0lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): final analysis of GRIFFIN","author":"Sborov","year":"2022"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0030","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1182\/blood-2022-162339","article-title":"Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): final analysis of griffin among clinically relevant subgroups","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.07.001_bib0031","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17474086.2020.1804356","article-title":"Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review","volume":"13","author":"Sanchez","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"29","key":"10.1016\/j.clml.2023.07.001_bib0032","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.07.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8004","volume":"39","author":"Moreau","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.07.001_bib0034","unstructured":"Daratumumab, VELCADE (Bortezomib), lenalidomide and dexamethasone compared to velcade, lenalidomide and dexamethasone in subjects with previously untreated multiple myeloma (Perseus). ClinicalTrials.gov. Accessed February 10, 2023."},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.07.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS)","volume":"37","author":"Sonneveld","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.07.001_bib0036","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.07.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: efficacy in high-risk patients","volume":"39","author":"Gay","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.07.001_bib0038","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2023.07.001_bib0039","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8011","article-title":"Daratumumab (DARA)\u00a0+\u00a0lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): a post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN","volume":"40","author":"Rodriguez","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2023.07.001_bib0040","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.07.001_bib0041","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2023.07.001_bib0042","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.07.001_bib0043","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0044","doi-asserted-by":"crossref","first-page":"10958","DOI":"10.1182\/blood-2022-166490","article-title":"The determination trial impact on upfront (vs delayed) autologous stem cell transplantation for transplant-eligible newly diagnosed multiple myeloma","volume":"140","author":"Dulka","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0045","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.001_bib0046","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","author":"Ragon","year":"2023","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.clml.2023.07.001_bib0047","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab\u00a0+\u00a0bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.07.001_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2023.07.001_bib0049","article-title":"Practical considerations for the daratumumab management in Portuguese routine clinical practice: recommendations from an expert panel of hematologists","volume":"11","author":"Geraldes","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.07.001_bib0050","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.clml.2023.07.001_sbref0051","series-title":"NCCN Guidelines: Prevention and Treatment of Cancer-Related Infections","year":"2022"},{"issue":"38","key":"10.1016\/j.clml.2023.07.001_bib0052","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/EDBK_205443","article-title":"Practical considerations for antibodies in myeloma","author":"Laubach","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2023.07.001_bib0053","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.001_bib0054","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-140056","article-title":"Effect of intravenous immunoglobulin on infections in multiple myeloma (MM) patients receiving daratumumab","volume":"136","author":"Lancman","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0055","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1182\/blood-2022-158472","article-title":"Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection-related hospitalizations in multiple myeloma patients","volume":"140","author":"Sheu","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.07.001_bib0056","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.07.001_bib0057","article-title":"Real world experience of daratumumab: evaluating lymphopenia and adverse events in multiple myeloma patients","volume":"10","author":"Cottini","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.07.001_bib0058","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2023.07.001_bib0059","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021013714","article-title":"Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma","volume":"139","author":"Henriquez","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.07.001_bib0060","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"The Lancet Haematology"},{"issue":"5","key":"10.1016\/j.clml.2023.07.001_bib0061","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.07.001_bib0062","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.07.001_bib0063","unstructured":"Daratumumab and Hyaluronidase-FIHJ Injection, for Subcutaneous use [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; 2022."},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.001_bib0064","article-title":"Subcutaneous daratumumab with rapid corticosteroid tapering in relapsed or refractory multiple myeloma patients: part 3 update of the open-label, multicenter, phase 1b Pavo study","volume":"138","author":"Nahi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.001_bib0065","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720987075","article-title":"Subcutaneous daratumumab and hyaluronidase-FIHJ in newly diagnosed or relapsed\/refractory multiple myeloma","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.clml.2023.07.001_bib0066","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-023-00801-1","article-title":"Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience","volume":"13","author":"Maples","year":"2023","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:54Z","timestamp":1761871434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002100"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}